Interestingly, most of these inhibitors are multikinase inhibitors and often exhibit broad-spectrum activity, targeting kinases such as TAM family members TYRO3 and MERTK; as well as other RTKs such as vascular endothelial growth factor receptor (VEGFR), MET, FLT3, recepteur d’origine nantais (RON), and AURORA A/B in addition to AXL, which can contribute to their therapeutic efficacy in AML. The gene discussed is MET; the disease is acute myeloid leukemia.